TRIVENI TURBINE LIMITED
Geojit BNP Paribas
Broker Research reports: latest Upgrades
for all stocks
- This broker has downgraded this stock from it's previous report. (eg. - Buy->Hold)
- Broker has maintained previous recommendation but reduced share price target.
- This broker has upgraded this stock from it's previous report.(eg. - Sell->Hold)
- Broker has maintained previous recommendation but increased share price target.
RESEARCH REPORTS ALERTS
Load latest
Google or static link led you to an intermediate page.
- All Recent
- Upside
- Buy
- Sell
- Recent Upgrades
- Recent Downgrades
- IPO
- Sector Updates
- Most Recent
- Top Upside
Click on any table column to sort reports by date, stock name, broker, price, target, upside or recommendation.
| Summary | Date | Stock | Author | LTP | Target | Price at reco (Change since reco%) |
Upside(%) | Type | Report | Discuss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 May 2023 | Triveni Turbine |
Geojit BNP Paribas
|
563.70 | 410.00 | 399.50 (41.10%) | Target met |
Hold
|
||||
| 31 May 2023 | V-Guard Industries |
BOB Capital Markets Ltd.
|
374.85 | 270.00 | 251.05 (49.31%) | Target met |
Hold
|
||||
| 31 May 2023 | S Chand & Company |
Prabhudas Lilladhar
|
206.80 | 257.00 | 192.25 (7.57%) | Target met |
Buy
|
||||
| 31 May 2023 | Torrent Pharma |
Prabhudas Lilladhar
|
3173.00 | 1900.00 | 1835.80 (72.84%) | Target met |
Buy
|
||||
| 31 May 2023 | Sundaram Finance |
ICICI Securities Limited
|
5069.50 | 2446.00 | 2544.70 (99.22%) |
Hold
|
Valuations limit the upside considering the balanced growth approach
ICICI Securities Limited
Sundaram Finance (Sundaram) reported strong FY23 earnings in key parameters such as standalone AUM growth (up 17% YoY), home finance AUM growth (up 18% YoY), standalone NIMs (5.3%) sustenance in rising interest rate regime and better asset quality (gross stage 3 as on Mar’23 stood at 1.66% vs 2.2% in Mar’22).
|
||||
| 31 May 2023 | Aurobindo Pharma |
KRChoksey
|
1195.90 | 665.00 | 658.60 (81.58%) | Target met |
Hold
|
Stable performance across the geographies
KRChoksey
Aurobindo Pharma had a satisfactory performance in the current quarter due to stable demand and pricing conditions across their portfolio and geographical regions. In Q4FY23, the company's revenue reached INR 64,730 mn, showing an 11.4% increase compared to the previous year and a 1.0% increase compared to the previous quarter.
|
|||
| 31 May 2023 | Coal |
Motilal Oswal
|
392.80 | 290.00 | 241.25 (62.82%) | Target met |
Buy
|
||||
| 31 May 2023 | Ador Welding |
Edelweiss
|
901.50 | 1450.00 | 1146.10 (-21.34%) | Target met |
Buy
|
||||
| 31 May 2023 | Karnataka Bank |
Axis Direct
|
196.44 | 175.00 | 151.40 (29.75%) | Target met |
Buy
|
||||
| 31 May 2023 | Heidelberg Cement |
Axis Direct
|
193.52 | 165.00 | 171.70 (12.71%) |
Hold
|
|||||
|
more
loading
|
|||||||||||
* Please note that subscribers can download a maximum of 300 reports a month and 70 reports everyday.